Parenteral fish oil: An adjuvant pharmacotherapy for coronavirus disease 2019?

Raquel S Torrinhas,Philip C Calder,Gabriela O Lemos,Dan L Waitzberg,Raquel S. Torrinhas,Philip C. Calder,Gabriela O. Lemos,Dan L. Waitzberg

DOI: https://doi.org/10.1016/j.nut.2020.110900

IF: 4.893

2021-01-01

Nutrition

Abstract:The new coronavirus 2 associated to severe acute respiratory syndrome (SARS-CoV-2), surprisingly, does not affect only the lung. The severe response to SARS-CoV-2 appears to include a "cytokine storm", which indicates a state of hyperinflammation and subsequent dysfunction of multiple organs and tissues in the most severe cases. This could be the reason why populations at highest risk of death from the SARS-CoV-2 infection-induced disease (COVID-19) are those suffering from chronic low-grade inflammation, but prone to hyperinflammation - advanced age, obesity, type 2 diabetes, hypertension and metabolic syndrome. Inflammation resolution is strongly dependent on lipid mediators, the specialized pro-resolution mediators (SPMs). Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are precursors of very potent SPMs, including resolvins, protectins and maresins. In addition, they are associated with a less aggressive inflammatory initiation, after competing with omega-6 fatty acids for eicosanoid synthesis. Therefore, it makes sense to consider the use of n-3 PUFAs for clinical management of COVID-19 patients. N-3 PUFAs may be given by oral, enteral or parenteral routes, but the parenteral route favors their faster incorporation into plasma phospholipids, blood cells and tissues. Here, we discuss these aspects to propose the parenteral infusion of n-3 PUFAs as an adjuvant immunepharmacotherapy for hospitalized patients with COVID-19.

nutrition & dietetics